Request Demo
Last update 23 Jan 2025
BGB-B3227
Last update 23 Jan 2025
Overview
Basic Info
Drug Type Bispecific killer cell engager (BiKE) |
Synonyms MUC1 x CD16A Bispecific antibody(BeiGene) + [1] |
Target |
Mechanism CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators), MUC1 inhibitors(Mucin-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with BGB-B3227NCT06540066
A Multicenter, Open-label, Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B3227 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced or Metastatic Solid Tumors
100 Clinical Results associated with BGB-B3227
Login to view more data
100 Translational Medicine associated with BGB-B3227
Login to view more data
100 Patents (Medical) associated with BGB-B3227
Login to view more data
100 Deals associated with BGB-B3227
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 1 | US | 30 Aug 2024 | |
| Advanced cancer | Phase 1 | CN | 30 Aug 2024 | |
| Advanced cancer | Phase 1 | IT | 30 Aug 2024 | |
| Metastatic Solid Tumor | Phase 1 | CN | 30 Aug 2024 | |
| Metastatic Solid Tumor | Phase 1 | US | 30 Aug 2024 | |
| Metastatic Solid Tumor | Phase 1 | IT | 30 Aug 2024 | |
| Neoplasm Metastasis | Phase 1 | IT | 30 Aug 2024 | |
| Neoplasm Metastasis | Phase 1 | US | 30 Aug 2024 | |
| Neoplasm Metastasis | Phase 1 | CN | 30 Aug 2024 | |
| Solid tumor | Phase 1 | IT | 30 Aug 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free